Treatment patterns, clinical and economic outcomes of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer receiving ceritinib: a retrospective observational claims analysis

References

• Sullivan I, Planchard D. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol. 2016;8:32–47.
   PubMed Web of Science ®Google Scholar
• Kazandjian D, Blumenthal GM, Chen HY, et al. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist 2014;19:e5–11.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–2394.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–2177.
   PubMed Web of Science ®Google Scholar
• Chun SG, Choe KS, Iyengar P, et al. Isolated central nervous system progression on crizotinib: an achilles heel of non-small cell lung cancer with EML4-ALK translocation? Cancer Biol Ther. 2012;13:1376–1383.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011;71:6051–6060.
   PubMed Web of Science ®Google Scholar
• Wu J, Savooji J, Liu D. Second- and third-generation ALK inhibitors for non-small cell lung cancer. J Hematol Oncol. 2016;9:1–7.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Solomon B. [Internet]. Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer. 2016; [cited 2016 Sept]. Available from: http://www.uptodate.com/contents/anaplastic-lymphoma-kinase-alk-fusion-oncogene-positive-non-small-cell-lung-cancer
   Google Scholar
• Peters S. Emerging options after progression during crizotinib therapy. J Clin Oncol. 2016;34:643–645.
   PubMed Web of Science ®Google Scholar
• Kayaniyil S, Hurry M, Wilson J, et al. Treatment patterns and survival in patients with ALK-positive non-small-cell lung cancer: a Canadian retrospective study. Curr Oncol. 2016;23:e589–ee97.
   PubMed Web of Science ®Google Scholar
• Awad MM, Shaw AT. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol. 2014;12:429–439.
   PubMedGoogle Scholar
• Food and Drug Administration (FDA) [Internet]. Highlights of prescribing information. Zykadia® (ceritinib). 2017 [cited 2017 Aug]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205755s012lbl.pdf
   Google Scholar
• Khozin S, Blumenthal GM, Zhang L, et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res. 2015;21:2436–2439.
   PubMed Web of Science ®Google Scholar
• Raedler LA. Zykadia (Ceritinib) approved for patients with crizotinib-resistant ALK-positive non–small-cell lung cancer. Am Health Drug Benefits. 2015;8(Spec Feature):163–166.
   Google Scholar
• Crino L, Ahn MJ, De Marinis F, et al. Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2. J Clin Oncol. 2016;34:2866–2873.
   PubMed Web of Science ®Google Scholar
• Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 2017;389:917–929.
   PubMed Web of Science ®Google Scholar
• Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4:662.
   PubMed Web of Science ®Google Scholar
• Bendaly E, Dalal AA, Culver K, et al. Treatment patterns and early outcomes of ALK-positive non-small cell lung cancer patients receiving ceritinib: a chart review study. Adv Ther. 2017;34:1145–1156.
   PubMed Web of Science ®Google Scholar
• Cho BC, Kim DW, Bearz A, et al. ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol. 2017;12:1357–1367.
   PubMed Web of Science ®Google Scholar
• Cho B, Obermannova R, Bearz A, et al. Efficacy and updated safety of ceritinib (450 mg or 600 mg) with low-fat meal vs 750 mg fasted in ALK + metastatic NSCLC. International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer, October 2017, Yokohama, Japan. 2017 [cited 2017 Nov]. [Internet]; Available from: https://s3.amazonaws.com/iaslc/pdf/WCLC2017_Abstract_Book_Web.pdf
   Google Scholar
• Agency for Healthcare Research and Quality [Internet]. HCUP Methods Series. Comorbidity Software Documentation. 2004 [cited 2016 Sept]. Available from: https://www.hcup-us.ahrq.gov/reports/methods/ComorbiditySoftwareDocumentationFinal.pdf
   Google Scholar
• American Psychiatric Association [Internet]. Diagnostic and Statistical Manual of Mental Disorders (DSM–5). 2016 [cited 2016 Sept]. Available from: https://www.psychiatry.org/psychiatrists/practice/dsm
   Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130–1139.
   PubMed Web of Science ®Google Scholar
• Dziadziuszko R, Kim D-W, Bearz A, etet al. P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK + Metastatic NSCLC. J Thoracic Oncol. 2017;12:S1184.
   Web of Science ®Google Scholar
• Guerin A, Sasane M, Wakelee H, et al. Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy. Curr Med Res Opin. 2015;31:1587–1597.
   PubMed Web of Science ®Google Scholar
• European Society for Medical Oncology (ESMO) [Internet]. Ceritinib improves progression-free survival in phase 3 trial of ALK rearranged lung cancer. 2016 [cited 2016 Sept]. Available from: https://www.eurekalert.org/pub_releases/2016-10/esfm-cip100816.php
   Google Scholar